Day One Biopharmaceuticals Charts Ambitious 2026 Path With $225M-$250M OJEMDA Revenue Target Amid 172% YoY Surge

Day One Biopharmaceuticals Inc. (DAWN) is capitalizing on remarkable momentum heading into 2026, with the company setting an aggressive revenue guidance that signals confidence in its flagship OJEMDA asset’s staying power in the pediatric low-grade glioma market. The biopharmaceutical firm disclosed forward-looking projections ahead of its presentation at the 44th Annual J.P. Morgan Healthcare Conference, offering investors a window into its commercial trajectory.

2025 Performance Demonstrates Exceptional YoY Growth

The year-over-year performance tells the story. OJEMDA generated $155.4 million in full-year 2025 net product revenue, reflecting a striking 172% increase compared to 2024 results. In the fourth quarter alone, the drug brought in approximately $52.8 million in net product revenue, showcasing a 37% sequential expansion from Q3. This acceleration was fueled by mounting patient adoption and surging prescription volumes that hit 1,394 scripts in Q4—a testament to OJEMDA’s expanding footprint as a therapeutic option in its indication.

2026 Guidance Points to Sustained Growth Trajectory

Building on this foundation of robust performance and year-over-year gains, Day One is guiding 2026 U.S. OJEMDA net product revenue between $225 million and $250 million. At the midpoint, this projection implies approximately 53% growth from 2025 levels, signaling the company’s conviction that the drug’s commercial penetration remains in its early-to-mid innings.

The company’s strategic priorities for the year center on cementing OJEMDA’s position as the standard-of-care therapy in the second-line pediatric low-grade glioma space by improving patient persistence and cultivating new patient initiations. Additionally, Day One is pursuing international expansion through established partnerships, broadening the revenue potential beyond the U.S. market.

Pipeline Progression and Clinical Catalysts

Beyond the near-term OJEMDA narrative, Day One’s development programs are advancing on multiple fronts. The company expects to complete enrollment in its pivotal Phase 3 FIREFLY-2 trial evaluating OJEMDA in first-line pLGG during the first half of 2026. A mid-2027 data readout is anticipated, with potential regulatory approval possible in 2028—a critical milestone that could expand the drug’s addressable market considerably.

The Emi-Le program remains on track to deliver Phase 1 clinical data by mid-2026 with a path toward registration. Meanwhile, initial results from the Phase 1a trial of DAY301, a PTK7-targeted antibody drug conjugate, are expected in the second half of 2026, adding additional pipeline optionality.

Financial Position and Stock Movement

As of December 31, 2025, ahead of the Mersana acquisition completion, Day One reported approximately $441.1 million in cash, cash equivalents, and short-term investments, providing a solid runway for its development and commercialization initiatives.

It’s worth noting that DAWN shares closed at $8.94 on January 9 at 4:00 PM EST, down $0.31 or 3.35% from the previous session. However, the stock demonstrated resilience in after-hours trading, rebounding sharply to $10.35 at 11:13 PM EST—a gain of $1.41 or 15.77%—likely reflecting investor enthusiasm over the forward guidance and growth projections.

The financial metrics and revenue results disclosed remain preliminary and subject to adjustment. The company’s complete financial report for Q4 and full-year 2025 is expected in February 2026.